BioNTech Investor Day Presentation Deck

Unique combination potential across platforms Selected examples in the clinic LYTNI mRNA cancer vaccines Y Approved anti-PD-1/PD-L1 Vaccine-induced T-cell response expansion through PD1 blockade Several Phase 1 and Phase 2 trials ongoing for both FixVac and iNeST platforms in combination with anti-PD1 LAIN) LATIN mRNA cancer vaccines mRNA-encoded cytokines Vaccine-induced T-cell response amplification through RiboCytokines BNT151, BNT 153: IL-2 RiboCytokines in preclinical studies INLAT Engineered cell therapies mRNA cancer vaccines Autologous CAR T-cell therapy vaccine-amplified T-cell response BNT211: Ongoing Phase 1 trial across multiple tumors BIONTECH 94

View entire presentation